Moderna cancer vaccine stops melanoma returning: what’s next for personalized treatments?
Hub Director A/Prof. Seth Cheetham gave expert comment to Nature on Phase III results for intismeran, the Moderna and Merck personalised mRNA cancer vaccine that reduced the risk of melanoma returning. He described it as the first large-scale trial to report data for a personalised mRNA cancer vaccine, and a result that strengthens the wider field.
Read in Nature →
New melanoma vaccine reduces risk of cancer return and spread during trial
Hub Director A/Prof. Seth Cheetham appeared on 10 News to discuss the Phase III melanoma result, which found the personalised vaccine can prevent melanoma returning or spreading in high-risk patients.
Watch on YouTube →
Harnessing mRNA for more targeted cancer treatment
Tour de Cure funding will support two researchers in the Hub. Dr Liam O’Brien is engineering synthetic cytokines that act on tumours while sparing healthy tissue, and PhD scholar Hannah Tompkins is developing mRNA vaccines that make treatment-resistant cancer cells visible to the immune system.
Read full article →
From discovery to the clinic: Seth Cheetham takes the helm at NBF
A/Prof. Seth Cheetham has been appointed Director of the National Biologics Facility (NBF), where he will help bridge the gap between university research discoveries and clinical development of breakthrough medicines.
Read full article →
From Tadpoles to Therapeutics: Laura’s journey to AIBN
Dr Laura Leighton, a postdoctoral fellow at AIBN’s BASE facility, applies her lifelong curiosity about biology to advancing mRNA therapeutics, making these medicines safer and more targeted.
Read full article →
AIBN researchers secure nearly $5 million in ARC Fellowship funding
A/Prof. Seth Cheetham received a $1.13M ARC Future Fellowship to develop ultra-stable “cloaked” mRNAs that could enhance manufacture efficiency and stability while reducing production costs.
Read full article →Australian trial of personalised vaccines to treat children with deadly brain cancers
A world-first clinical trial will test personalised mRNA vaccines for children with advanced brain tumours. The PaedNEO-VAX study, funded by a $2.578 million Australian Government investment, will use genome sequencing to design customised vaccines across 8 paediatric hospitals in Australia.
Read full article →
Getting personal in the fight against cancer
The University of Queensland has established a new laboratory dedicated to designing, manufacturing and delivering personalised mRNA cancer vaccines, addressing a critical gap in Australia's drug development infrastructure.
Read full article →
How personalised mRNA vaccines could revolutionise cancer treatment
Hub Director A/Prof. Seth Cheetham presents at TEDxUQ on how custom-designed mRNA vaccine technology could change how cancers are treated, enabling treatments tailored to each individual patient.
Watch on YouTube →